Search PubMed⌕ Search

Biomedical subjects

J Rovner

Publications and source records attributed to J Rovner.

54 records · Page 3Linked to original sources
PubMed1995

Physician management companies: are they a good choice for doctors?

To many of the physicians who've signed with them, physician management companies (PMCs) seem like the answer to a prayer. The practice gets needed capital for growth, professional management, and managed care contracting expertise from a partner that has the doctors' best interests at heart--or does it? HSL looks at four leading PMCs to identify the pros and cons of partnering with them.

Capital Financing↗
PubMed1995

Reengineering governance to make mergers work.

Mergers are designed to trim excess capacity, but they can't if powerful local boards thwart restructuring efforts. UniHealth discovered that the hard way when local trustees stalled efforts to close a hospital; investment bankers told the system to clean up its board act. HSL examines how UniHealth, BJC, Lifespan and others are reshaping governance to act in their system's best interests.

Community Health Planning↗
PubMedDate not supplied

[The intercontinental schizophrenia outpatient health outcomes study (IC-SOHO): initial 6 month findings of the sample in Latin America].

The IC-SOHO study was designed to supply information on antipsychotic treatments in the real clinical practice by assessment of a large and diverse sample population with schizophrenia. This document describes the findings of the first 6 months of IC-SOHO in Latin America. To date, this is the largest observational study of its type in this region. In this observational and prospective study, those out-patients with schizophrenia, who require a change or initiation of antipsychotic medication are hospitalized. Effectiveness was evaluated using the Clinical Global Impression-Seriousness (CGI-S) grading scale. Tolerability was assessed by questionnaires on adverse events and weight measurements. Herein, the comparisons between olanzapine (monotherapy), risperidone (monotherapy) and conventional antipsychotics (monotherapy and combined therapy) are presented. As a whole, 7,658 patients participated in the ICSOHO; n=2,671 from 11 countries of Latin America that were included in this report. At 6 months, the proportion of patients who responded to olanzapine was significantly greater than those who responded to risperidone or conventional antipsychotics (p<0.001). Patients from the olanzapine group had greater improvements in all the symptom domains, including general, positive, negative, depressive and cognitive symptoms in comparison with risperidone (p<0.05) or conventional antipsychotics (p < 0.001). Extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) decreased from baseline in the groups treated with olanzapine and risperidone, but increased in the conventional group. The adverse events related with the sexual function were more prominent in the conventional group. Weight gain was observed in each treatment group, although the patients from the olanzapine group had greater weight grain followed by those of risperidone and then by those of conventional antipsychotics. Our findings in this population of the Latin American sample emulate the results of other studies in different samples, where it was found that olanzapine was more effective and better tolerated than risperidone or conventional antipsychotics.

Adult↗